InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（11 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
11
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the full record of transactions filed by Lorrain Daniel S., Chief Scientific Officer. Director active across 1 company, notably Contineum Therapeutics, Inc.. Aggregated, 16 filings have been published. Split: 0 buy · 11 sells. Total volume traded: €430k. History available since 18 November 2024. The latest transaction was disclosed on 8 July 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Lorrain Daniel S.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报16 总计
1,015 股@ US$1.010.0002% mcap0.2% 占其流量Class A Common StockSEC:0001628280-26-047909:0
1,015 股@ US$16.000.0028% mcap3.3% 占其流量Class A Common StockSEC:0001628280-26-047909:1
25 股@ US$1.010.0000% mcap0.0% 占其流量Class A Common StockSEC:0001628280-26-047909:2
25 股@ US$16.000.0001% mcap0.1% 占其流量Class A Common StockSEC:0001628280-26-047909:3
4,170 股@ US$13.15640.011% mcap8.2% 占其流量Class A Common StockSEC:0001628280-26-039641:0
3,870 股@ US$13.060.010% mcap10.3% 占其流量Class A Common StockSEC:0001628280-26-029435:0
4,170 股@ US$13.43260.011% mcap11.6% 占其流量Class A Common StockSEC:0001628280-26-023949:0
4,170 股@ US$15.008412.7% 占其流量Class A Common StockSEC:0001437749-26-006422:0
4,300 股@ US$1.010.0009% mcap0.9% 占其流量Class A Common StockSEC:0001437749-26-005889:0
100 股@ US$1.010.0% 占其流量Class A Common StockSEC:0001437749-26-004912:0
400 股@ US$1.010.1% 占其流量Class A Common StockSEC:0001437749-26-004122:0
3,000 股@ US$14.82290.0088% mcap9.0% 占其流量Class A Common StockSEC:0001437749-26-003212:0
3,670 股@ US$10.34830.0076% mcap7.8% 占其流量Class A Common StockSEC:0001437749-26-000616:0
4,170 股@ US$12.23240.010% mcap10.4% 占其流量Class A Common StockSEC:0001437749-25-038936:0
1,010 股@ US$16.01722.7% 占其流量Class A Common StockSEC:0001437749-24-036349:0
6,091 股@ US$16.373816.5% 占其流量Class A Common StockSEC:0001437749-24-035887:0
16 条申报中的 16 条
About Lorrain Daniel S.
Lorrain Daniel S. serves as Chief Scientific Officer at Contineum Therapeutics, Inc. In this role, he oversees the company's research and development activities. His expertise in biological sciences enables him to lead innovation projects and ensure product quality. Daniel plays a key role in implementing research and development strategies.
